Cagent Vascular published a case report by Dr. Mazin Foteh detailing Serration Remodeling Therapy (SRT) for treating a 5.4 cm abdominal aortic aneurysm with under-expanded iliac stents.
Published
Signal category
Research & Knowledge
Quote
“In his upcoming case report, Dr. Mazin Foteh makes the case for Serration Remodeling Therapy (SRT): concentrating point force along the neointima to disrupt hyperplastic tissue and expand under-expanded stents at low inflation pressure, without the rupture risk of high-pressure PTA, the missed hyperplasia of lithotripsy, or the stent-frame risk of atherectomy.”
— Cagent Vascular team
Company
Cagent Vascular
It’s time for a new standard of care. It’s time for Serranator.
- Industry
- Medical Equipment Manufacturing
- Location
- Wayne, US
- Company size
- 105 employees
Cagent Vascular is the first and only company to commercialize an angioplasty balloon with integrated serrations, introducing a new category of endovascular treatment: Serration Remodeling Therapy (SRT). Headquartered in Wayne, PA, our mission is to improve outcomes for patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI) by changing the way physicians treat diseased vessels. Our flagship device, the Serranator® PTA Serration Balloon Catheter, creates controlled micro-fissures in the arterial wall, driving vessel wall remodeling, not just dilation. The result: greater lumen gain, reduced recoil, and improved vessel compliance across lesion morphologies. It's time for a new standard of care. It starts with Serranator.
Founded 2014